Lateral Flow Assays Market Size, Growth, Share & Trends Analysis

Age-related physiological changes and metabolic inefficiencies often result in chronic diseases such as cystic fibrosis, hepatitis, cardiovascular disorders, and cancer. Geriatric individuals (65 years and above) are more susceptible to these diseases and infectious diseases due to weakened immune systems. According to a report by The Lancet, there were 1.1 billion individuals aged 60 years or older in 2022, accounting for 13.9% of the global population of 7.9 billion. This senior population is predicted to double in the next thirty years, reaching 2.1 billion by 2050, or 22% of the world’s total population. All regions are expected to experience an increase in the size of the older population between 2020 and 2050.

While lateral flow assay (LFA) tests offer the benefits of rapid results, ease of use, and cost-effectiveness, one of their primary limitations remains variability in accuracy and reliability, particularly in comparison to laboratory-based diagnostic methods such as ELISA or PCR. LFA tests often face challenges in sensitivity and specificity, especially in cases where analyte concentrations are close to the detection limit or when samples are collected or handled improperly. This can lead to false-negative or false-positive results, which significantly compromise clinical decision-making and patient outcomes. In tuberculosis screening, certain lateral flow-based antigen detection tests have shown limited sensitivity in HIV-positive individuals due to low bacterial loads, resulting in underdiagnosis. Similarly, in malaria testing, some LFA devices have demonstrated reduced performance in detecting low-parasite-density infections, which is critical in low-transmission or elimination settings.

Lateral flow assays have evolved rapidly in the last two decades and are routinely used in POC and diagnostic applications. Although lateral flow tests are widely used for infectious disease diagnostics, cardiac disease diagnosis, and veterinary applications, their use has expanded into several new areas over the past few years. Saliva diagnostics, behavioral health, agriculture (genetically modified organism detection and crop quality testing), biowarfare (anthrax detection), environmental testing (detection of contaminating enzymes in manufacturing plants), and food microbiology (detection of E. coli O157, Salmonella, Listeria, and other food spoilage organisms) have emerged as new application areas for lateral flow assays.

Owing to reimbursement issues, lateral flow assay-based diagnostic tests have witnessed limited adoption in several countries across the globe. The rise in healthcare expenditure is compelling insurance payers to question and analyze the necessity of new diagnostic tests. Also, payers are moving from fee-for-service reimbursement systems toward fee-for-value-based reimbursement systems. As a result, a diagnostic test that enables a clinician to decide whether to go for a particular treatment does not receive adequate reimbursement and is abandoned or underinvested.